PHASE I STUDY OF OMBRABULIN IN COMBINATION WITH CISPLATIN (CDDP) ADMINISTERED EVERY 3 WEEKS TO JAPANESE PATIENTS WITH ADVANCED SOLID TUMORS

被引：0
|
作者：
Takahashi, S.
Ura, T. [1 ]
Nakano, K.
Chin, K.
Yokoyama, M.
Hatake, K.
Yokota, T. [1 ]
Shitara, K. [1 ]
Muro, K. [1 ]
Aoyama, T.
机构：
[1] Aichi Canc Ctr Hosp, Dept Clin Oncol, Aichi, Japan
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：110 / 110
页数：1
相关论文
共 50 条
  • [21] Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours
    Yamamoto, Nobuyuki
    Boku, Narikazu
    Minami, Hironobu
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 65 (01) : 129 - 136
  • [22] Phase I study of larotaxel administered as a 1-h intravenous infusion every 3 weeks to Japanese patients with advanced solid tumours
    Nobuyuki Yamamoto
    Narikazu Boku
    Hironobu Minami
    Cancer Chemotherapy and Pharmacology, 2009, 65 : 129 - 136
  • [23] An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors
    H. Murakami
    T. Kurata
    Y. Onozawa
    J. Watanabe
    A. Ono
    T. Takahashi
    N. Yamamoto
    Y. Fujisaka
    H. Kiyota
    H. Hayashi
    K. Tanaka
    K. Nakagawa
    S. Kuroda
    Cancer Chemotherapy and Pharmacology, 2014, 73 : 623 - 630
  • [24] An open-label, dose-escalation, safety, and pharmacokinetics phase I study of ombrabulin, a vascular disrupting agent, administered as a 30-min intravenous infusion every 3 weeks in Japanese patients with advanced solid tumors
    Murakami, H.
    Kurata, T.
    Onozawa, Y.
    Watanabe, J.
    Ono, A.
    Takahashi, T.
    Yamamoto, N.
    Fujisaka, Y.
    Kiyota, H.
    Hayashi, H.
    Tanaka, K.
    Nakagawa, K.
    Kuroda, S.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (03) : 623 - 630
  • [25] Pazopanib (P) and cisplatin (CDDP) in patients with advanced solid tumors: A UNICANCER phase I study.
    Dieras, Veronique
    Bachelot, Thomas
    Campone, Mario
    Isambert, Nicolas
    Joly, Florence
    Le Toumeau, Chrlstophe
    Cassler, Philippe Alexandre
    Bompas, Emmanuelle
    Fumoloau, Pierre
    Noal, Sabine
    Orsini, Christina
    Jimenez, Marta
    Imbs, Diane Charlotte
    Chatelut, Etienne
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [26] Phase I and Pharmacokinetic Study of ABI-007, Albumin-bound Paclitaxel, Administered Every 3 Weeks in Japanese Patients with Solid Tumors
    Yamada, Kazuhiko
    Yamamoto, Noboru
    Yamada, Yasuhide
    Mukohara, Toru
    Minami, Hironobu
    Tamura, Tomohide
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2010, 40 (05) : 404 - 411
  • [27] Phase I study of lurbinectedin (PM01183) in combination with cisplatin (CDDP) with or without aprepitant in patients (pts) with advanced solid tumors
    Forster, M.
    Sessa, C.
    Von Moos, R.
    Brown, N.
    Metaxas, Y.
    Griguolo, G.
    Lardelli, P.
    Iglesias, J.
    Fernandez-Teruel, C.
    Jandali, U.
    Soto-Matos, S. M.
    Stathis, A.
    EUROPEAN JOURNAL OF CANCER, 2017, 72 : S134 - S134
  • [28] Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors
    Yasuhide Yamada
    Tomohide Tamura
    Noboru Yamamoto
    Tatsu Shimoyama
    Yutaka Ueda
    Haruyasu Murakami
    Hitoshi Kusaba
    Yoshikazu Kamiya
    Hideo Saka
    Yusuke Tanigawara
    J. Patrick McGovren
    Yutaka Natsumeda
    Cancer Chemotherapy and Pharmacology, 2006, 58 : 173 - 182
  • [29] Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors
    Yamada, Y
    Tamura, T
    Yamamoto, N
    Shimoyama, T
    Ueda, Y
    Murakami, H
    Kusaba, H
    Kamiya, Y
    Saka, H
    Tanigawara, Y
    McGovren, JP
    Natsumeda, Y
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2006, 58 (02) : 173 - 182
  • [30] Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (Caelyx) administered every 2 weeks in patients with advanced solid tumors
    Mavroudis, D
    Kouroussis, C
    Kakolyris, S
    Agelaki, S
    Kalbakis, K
    Androulakis, N
    Souglakos, J
    Samonis, G
    Georgoulias, V
    ONCOLOGY, 2002, 62 (03) : 216 - 222
12345